Skip to main content
INNOVACAP · Health Care · 2026-08-07

Innova Captab Ltd

4.9WatchEven +1.3Stage 2 · wk 10In scan: Pullback Hunter · Prop ScanMARKET: BULL TOPPING · 2026-08-07
₹944.5
-1.00% today
₹5,405 Cr · Mid cap
About this companyHealth Care· Pharmaceuticals
Expand ▾

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Visit company website →
P/E (TTM)
34.4
Forward 19.0
Earnings Growth (YoY)
+28.6%
Revenue +42.3%
ROE
+13.7%
Profit margin +8.6%
Dividend Yield
0.47%
P/B 4.7
vs 52W High
-6.6%
₹642.8 lo₹1,011.3 hi
6.6% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 10
1w13w26w
Week 10 — early Stage 2, building
How long this stock has been in Stage 2. The sweet spot is typically 13–26 weeks — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
20.1%
200 DMA: ₹786.2 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.37x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
MA20 rolling over · -1.0% vs MA50 +5.2%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
Sector
Health Care
↑ Building
Stage 2%
51.6%
20d Δ
+1.6pp
1M return
+3.1%
3M return
+11.6%
Sector Stage-2 % · last 20 days
This stock ranks #55 of 79 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
50.5%
20d Δ
+0.5pp
1M return
+1.9%
3M return
+11.7%
Industry Stage-2 % · last 20 days
Ranks #37 of 53 Stage 2 stocks in this industry.
Price + Volume Chart
Loading price chart…
Stage Cycle Timeline2023-12-29 → 2026-08-07
S? 43w
S2 16w
S4 28w
2023-12-292026-08-07
S1S2S3S4Setup score (0–10, dashed line at 5)
S? 43w → S2 16w → S3 10w → S4 2w → S1 1w → S2 4w → S1 2w → S4 5w → S1 8w → S4 28w → S1 6w → S2 10w current
Total tracked: 135 weeks across 12 stage runs.
1M
-4.7%
3M
+7.9%
6M
+36.8%
YTD
+33.7%
1Y
+3.2%
Scan Membership
Pullback Hunter
Latest: 2026-08-06
Prop Scan
Latest: 2026-08-06
60 appearances in last 60 days. First seen: 2026-06-08.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-08-07S2
Wk 10 · Vol x
2026-08-06S2
Wk 10 · Vol x
2026-08-05S2
Wk 10 · Vol x
2026-08-04S2
Wk 10 · Vol x
2026-08-03S2
Wk 9 · Vol x
2026-07-31S2
Wk 9 · Vol x
2026-07-30S2
Wk 9 · Vol x
2026-07-29S2
Wk 9 · Vol x
2026-07-28S2
Wk 9 · Vol x
2026-07-27S2
Wk 8 · Vol x
2026-07-24S2
Wk 8 · Vol x
2026-07-23S2
Wk 8 · Vol x
Sector Peers — Stage 2All →
DIVISLAB
wk 12 · -3.6% from hi
8.5
LAURUSLABS
wk 16 · -0.3% from hi
8.4
PPLPHARMA
wk 4 · 0.0% from hi
8.2
LALPATHLAB
wk 9 · 0.0% from hi
7.9
SHILPAMED
wk 13 · 0.0% from hi
7.8
Moving averages & range
50 DMA
₹948.2
200 DMA
₹786.2
52W High
₹1,011.3
52W Low
₹642.8
5D Low
₹942
Resistance levels (recent highs)
20d High
₹1,011.3
60d High
₹1,011.3
120d High
₹1,011.3
250d High
₹1,011.3
Next resistance
+7.1%
to 20d High

All analytics based on EOD data. Data as of 2026-08-07. Past data patterns are not indicative of future results. This page is a data analytics tool only.